Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.
New Review Article Explores Endotyping, B Cells & More
A case-based review examines B cells in Sjögren’s disease, the use of endotyping for patient stratification & prognostication, & lymphoma risk.
Air Pollution May Increase the Risk of RA & RA-Associated ILD
Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.
Gout Flares & the NLRP3 Inflammasome
Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as a new treatment option.
New Editor in Chief Has Expansive Vision for Arthritis & Rheumatology
Incoming Arthritis & Rheumatology Editor-in-Chief Dr. S. Louis Bridges Jr., MD, PhD, discusses his path to rheumatology and outlines his vision for the journal.
Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View
Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.
A&R Editor-in-Chief Daniel H. Solomon, MD, MPH, Reflects on the Journal, His Role & Its Future
New clinical features, opinion pieces and much more—outgoing Arthritis & Rheumatology Editor-in-Chief Daniel H. Solomon, MD, MPH, discusses how the journal has evolved and where it’s going.
Metabolic Syndrome & RA Treatment Response
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Weathering the Cytokine Storm: Macrophage Activation Syndrome in Adults & Children
Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.
Lung Cancer in RA & RA-ILD
Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.
- 1
- 2
- 3
- …
- 15
- Next Page »